// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg

Ekaterina Krauss - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Quantitative CT for the assessment of disease severity in interstitial lung disease

David G. Parr - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Eligibility for anti-fibrotic therapy of patients in British Thoracic Society (BTS UK IPF Registry varies according to the reference values used to calculate FVC

Phil Molyneaux - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Idiopathic pulmonary fibrosis (IPF: the patient journey

Vincent Cottin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Evolution of the ‘Indeterminate UIP’ HRCT pattern; a cohort snapshot

Andrew Achaiah - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Collagen1a1 mRNA expression in BAL cells is associated with disease progression and poor survival in ILDs

Eliza Tsitoura - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD

Eric White - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Clinical burden of idiopathic pulmonary fibrosis (IPF: physician and patient perception

Francesco Bonella - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Feasibility of a cardiopulmonary exercise test (CPET derived high-intensity interval training programme (HIIT in idiopathic pulmonary fibrosis (IPF

Tim Wallis - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Outcomes at Week 12 from three RCTs of sildenafil with and without antifibrotics in advanced IPF

Juergen Behr - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pirfenidone

Pirfenidone side-effect risk stratification: targeting nursing support at a single UK prescribing centre

Carmine Ruggiero - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pirfenidone

MUC2MUC5B and TOLLIP variants: no association with disease progression and survival in an IPF cohort

Carmel Stock - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pirfenidone

Inflammasome activation in airway macrophages and the lung microbiome in IPF

Athina Trachalaki - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A review of patients following a diagnosis of unclassified interstitial lung disease (ILD at a tertiary centre

Fiona Thompson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Single-arm observational study of a mobile app + home spirometry in idiopathic pulmonary fibrosis

Lynn Fox - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype

Maria Kokosi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic

Thomas Simpson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Oxygen enhanced MRI biomarkers of lung function in interstitial lung disease

Marta Tibiletti - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Ventilation defect quantification on 3He MRI through deep learning: the MESA COPD Study

Xuzhe Zhang - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Helium

Regional hyperpolarised 129-xenon diffusion-weighted MRI in patients with IPF

James Eaden - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved